Compositions and methods for modulating the immune system
View Patent ↗A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a T H 2 type cytokine bias, in addition PIF enhance endometrial receptivity by increasing adhesion molecules expression. PIF biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages. PIF peptides, which are immune modulators therefore may have diagnostic and non toxic therapeutic applications in improving fertility, reducing pregnancy loss as well may be useful when administered for the treatment of autoimmune diseases and for prevention xenotransplants rejection.
1. An antibody that binds specifically to PIF polypeptide comprising the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 10, or SEQ ID NO: 12.
2. The antibody of claim 1 , wherein the antibody is a polyclonal antibody, and wherein the antibody binds a PIF polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:7, and SEQ ID NO:10.
3. The antibody of claim 1 , wherein the antibody comprises a monoclonal or polyclonal antibody.
4. A composition for detecting the presence of PIF peptide in a fluid, the composition comprising:
PIF antibodies; and
the fluid,
wherein the PIF antibodies bind a PIF polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 12, and combinations thereof.
5. The composition of claim 4 , wherein the fluid is selected from the group consisting of serum, blood, urine, milk, saliva, embryo culture media, gestational tissues, fetal tissue and combinations thereof.
6. The composition of claim 4 , wherein the antibodies are labeled.
7. The composition of claim 4 , wherein the antibodies are chemically bonded to a substrate.
8. The composition of claim 4 , wherein the antibodies comprise a monoclonal or polyclonal antibody.
9. The antibody of claim 1 , wherein the half maximal inhibitory concentration is from about 500 pM to about 700 pM.
10. A method of assaying PIF in a sample comprising, obtaining a sample from a subject, mixing the sample with a detecting antibody and measuring the concentration of PIF in the sample.
11. The method of claim 10 , wherein the antibody assay, is an ELISA.
12. The method of claim 11 , wherein the assay is a sandwich ELISA.